The activated conformation of integrin β7 is a novel multiple myeloma–specific target for CAR T cell therapy,Nature Medicine

当前位置： X-MOL 学术 › Nat. Med. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

The activated conformation of integrin β7 is a novel multiple myeloma–specific target for CAR T cell therapy
Nature Medicine ( IF 58.7 ) Pub Date : 2017-11-06 , DOI: 10.1038/nm.4431
Naoki Hosen , Yukiko Matsunaga , Kana Hasegawa , Hiroshi Matsuno , Yuki Nakamura , Mio Makita , Kouki Watanabe , Mikako Yoshida , Kei Satoh , Soyoko Morimoto , Fumihiro Fujiki , Hiroko Nakajima , Jun Nakata , Sumiyuki Nishida , Akihiro Tsuboi , Yoshihiro Oka , Masahiro Manabe , Hiroyoshi Ichihara , Yasutaka Aoyama , Atsuko Mugitani , Takafumi Nakao , Masayuki Hino , Ryosuke Uchibori , Keiya Ozawa , Yoshihiro Baba , Seitaro Terakura , Naoki Wada , Eiichi Morii , Junichi Nishimura , Kiyoshi Takeda , Yusuke Oji , Haruo Sugiyama , Junichi Takagi , Atsushi Kumanogoh

The activated conformation of integrin β₇ is a novel multiple myeloma–specific target for CAR T cell therapy

The activated conformation of integrin β<sub>7</sub> is a novel multiple myeloma–specific target for CAR T cell therapy, Published online: 06 November 2017; doi:10.1038/nm.4431

NatureArticleSnippet(type=short-summary, markup=

Hosen et al. identify an active conformation of integrin beta-7 as a cancer-associated antigen in multiple myeloma, and engineer a CAR-T cell that shows efficacy against MM in a mouse model. These findings describe the first conformation-specific CAR-T cell and highlight the potential of conformational targets in cancer immunotherapy.

, isJats=true)

中文翻译：